GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Short-Term Debt

CAMP (Camp4 Therapeutics) Short-Term Debt : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Short-Term Debt?

Camp4 Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.

Camp4 Therapeutics Short-Term Debt Historical Data

The historical data trend for Camp4 Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Short-Term Debt Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Short-Term Debt
- - -

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial - - - - -

Camp4 Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Camp4 Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Camp4 Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Camp4 Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Short-Term Debt
Comparable Companies
ZURA CLYM KYTX VTYX CRBU XCUR WHWK ACOG ORMP VIGL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Website
https://www.camp4tx.com
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.